Real-world data confirms afamelanotide improves quality of life and light tolerance in erythropoietic protoporphyria patients, indicating effective treatment options.
The real-world data of the Austrian cohort confirm the effectiveness and safety of afamelanotide in EPP patients.
No takes yet. Share an insight, caveat, or question.
Seidl-Philipp et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: